The market reacted positively to the liquidity event, with Fortress shares rising 14% to $3.84 during morning trading. According to Chief Executive Lindsay Rosenwald, the voucher sale—combined with recent FDA approvals for the treatments Emrosi, Unloxcyt, and Zycubo—has positioned the company to reach profitability in 2024. The stock has seen a dramatic climb over the last 12 months, gaining nearly 150% in value.

Strategic Asset Monetization

The voucher was originally granted by the FDA following the approval of Zycubo, a copper-based therapy for Menkes disease. While Sentnyl Therapeutics assumed responsibility for the development and commercialization of the drug, the Priority Review Voucher was transferred back to Cyprium under the terms of their existing agreement. The identity of the buyer for the $205 million credit has not been disclosed.

Under the terms of the transaction, Cyprium is obligated to pay 20% of the proceeds to the Eunice Kennedy Shriver National Institute of Child Health and Human Development, a division of the NIH. Despite this payout, Fortress remains eligible for sustained revenue through the following channels:

• Tiered royalties on global net sales of Zycubo.
• Development and sales milestones totaling up to $129 million.
• Capital realized from the recent sale of an additional subsidiary.

The transaction highlights the increasing market value of Priority Review Vouchers, which allow pharmaceutical companies to accelerate the review timeline for new drug applications. For Fortress, the sale represents a successful exit from a long-term development project while maintaining significant upside through future royalties.